

November 13, 2020

To  
Department of Corporate Services  
**BSE Limited**  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001  
Scrip Code: **BSE - 524500**

To  
Corporate Listing Department  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Plot No.C-1, G Block,  
BKC, Bandra (E), Mumbai 400 051  
Scrip Code: **NSE - KILITCH**

**Sub: Outcome of Board Meeting held on November 13, 2020**

Dear Sir/Madam,

We wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. November 13, 2020, have

- Considered & approved the Un-audited financial results of the company for the quarter and half year ended September 30, 2020.


In this connection please find enclosed the copy of Un-audited standalone & consolidated financial Results of the Company for the quarter and half year ended September 30, 2020 along with Limited Review Report by the Statutory Auditors of the Company as "Annexure-I".

The meeting commenced at 12:30 P.M. (IST) and concluded at 4:45 P.M.(IST)

The above is for information and dissemination to the public at large.

Thanking You,

Yours Faithfully,  
For **Kilitch Drugs (India) Limited**



**Mukund Mehta**  
Managing Director  
DIN: 00147876



Encl: as above



**Limited Review Report on Unaudited Quarterly/Half yearly Standalone Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
**The Board of Directors of**  
**Kilitch Drugs (India) Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter and half year ended 30th September, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We draw attention to Note 4 of the Statement, which describes the company's management evaluation of impact of Covid 19 pandemic on the its business, logistics etc. The Management has made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter/half year ended 30th September, 2020.

Our conclusion on the Statement is not modified in respect of these matters.



**A. M. GHELANI & COMPANY**  
**CHARTERED ACCOUNTANTS**

---

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A. M. Ghelani & Company**  
Chartered Accountants  
Firm Registration No. 103173W

**Chintan A. Ghelani**  
**Partner**  
Membership No. 104391



ICAI UDIN: 20104391AAAAFF5703

Place : Mumbai  
Date : 13<sup>th</sup> November, 2020

# KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701  
Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

( Rs.in Lakhs )

Sr. No.	Particulars	STANDALONE					
		Three Months Ended			Six Months Ended		Year Ended
		30/09/2020 Unaudited	30/06/2020 Unaudited	30/09/2019 Unaudited	30/09/2020 Unaudited	30/09/2019 Unaudited	31/03/2020 Audited
<b>1</b>	<b>Income</b>						
	Net Sales/ Income from operations	1,818.67	1,036.78	1,777.38	2,855.45	2,975.65	6,076.80
	Other Income	98.25	88.44	92.05	186.69	267.53	570.92
	<b>Total Income</b>	<b>1,916.92</b>	<b>1,125.22</b>	<b>1,869.43</b>	<b>3,042.14</b>	<b>3,243.18</b>	<b>6,647.72</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of Materials Consumed	820.01	687.51	817.52	1,507.52	1,700.60	3,648.61
	(b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	81.53	51.20	153.49	132.73	48.42	(73.48)
	(c) Employee Benefit Expenses	131.66	114.90	138.92	246.56	271.50	565.35
	(d) Finance Cost	17.84	29.32	16.44	47.16	31.54	71.59
	(e) Depreciation and Amortisation Expenses	28.45	27.42	23.75	55.87	46.23	115.30
	(f) Export Product Registration/Commission	76.58	50.20	85.99	126.78	210.87	448.15
	(g) Other Expenses	440.02	237.82	388.57	677.84	599.56	1,349.96
	<b>Total Expenses</b>	<b>1,596.09</b>	<b>1,198.37</b>	<b>1,624.68</b>	<b>2,794.46</b>	<b>2,908.72</b>	<b>6,125.48</b>
<b>3</b>	<b>Profit / (Loss) before Exceptional items (1-2)</b>	<b>320.83</b>	<b>(73.15)</b>	<b>244.75</b>	<b>247.68</b>	<b>334.46</b>	<b>522.24</b>
<b>4</b>	Exceptional Items	-	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) from ordinary activities before tax (3+4)</b>	<b>320.83</b>	<b>(73.15)</b>	<b>244.75</b>	<b>247.68</b>	<b>334.46</b>	<b>522.24</b>
<b>6</b>	Tax Expenses:						
	Current Tax	67.50	-	42.90	67.50	47.55	69.58
	Deferred Tax	(17.80)	(18.73)	(8.47)	(36.53)	12.15	6.95
<b>7</b>	<b>Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)</b>	<b>271.13</b>	<b>(54.42)</b>	<b>210.32</b>	<b>216.71</b>	<b>274.76</b>	<b>445.71</b>
<b>8</b>	Other Comprehensive Income (after tax)	96.59	184.43	(27.44)	281.02	(64.65)	(310.91)
<b>9</b>	<b>Total Comprehensive Income (after taxes) (7+8)</b>	<b>367.72</b>	<b>130.01</b>	<b>182.88</b>	<b>497.73</b>	<b>210.11</b>	<b>134.80</b>
<b>10</b>	Paid-Up equity share capital (Face Value Rs 10 per share)	1,547.91	1,547.91	1,543.42	1,547.91	1,543.42	1,543.42
<b>11</b>	Other Equity						13,621.29
<b>12</b>	<b>Earnings per share</b>						
	(a) Basic (not annualised)	1.75	(0.35)	1.36	1.40	1.78	2.89
	(b) Diluted (not annualised)	1.75	(0.35)	1.36	1.40	1.78	2.89

**Notes:**

- The above Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13th November, 2020.
  - The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
  - The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
  - The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. The Management has exercised due care and made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter/half year ended 30th September, 2020. The Company based on current estimates expects to recover the carrying amount of the above assets, net of provisions established.
- In view of the uncertainties regarding the nature and duration of the ongoing COVID-19 Pandemic, we are unable to predict the future impact on our business operations. However, the Company will continue to closely monitor the situation and take appropriate measures in an attempt to mitigate any adverse impact on its future economic conditions.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place : Mumbai  
Dated: 13th November, 2020



For and on behalf of the Board of Directors

*Mukund P. Mehta*  
**Mukund P. Mehta**  
Managing Director



**KILITCH DRUGS (INDIA) LIMITED**

**Balance Sheet**

**As at 30th September, 2020**

( Rs.in Lakhs )		
Particulars	As at 30th September, 2020	As at 31st March, 2020
<b>ASSETS</b>		
<b>Non-current assets</b>		
- Property, Plant and Equipment	734.90	761.63
- Capital work-in-progress	-	-
- Other Intangible Assets	4.90	5.02
<b>Financial assets</b>		
- Investments	7,044.62	7,026.51
- Loans/Advances	4,131.43	3,866.31
- Other Financial Assets	157.35	53.83
Deferred tax assets (Net)	132.71	96.18
<b>(A)</b>	<b>12,205.91</b>	<b>11,809.48</b>
<b>Current Assets</b>		
- Inventories	221.27	555.67
<b>Financial assets</b>		
- Investments	3,155.80	2,781.04
- Trade Receivables	1,701.26	1,700.58
- Cash & Cash Equivalents	83.50	272.26
- Other Financial Assets	0.87	2.54
Other Current Assets	515.82	289.69
<b>(B)</b>	<b>5,678.52</b>	<b>5,601.78</b>
<b>TOTAL ASSETS (A + B)</b>	<b>17,884.43</b>	<b>17,411.26</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
- Equity Share Capital	1,547.91	1,543.42
- Other Equity	14,119.02	13,621.29
<b>Equity attributable to Owner</b>	<b>15,666.93</b>	<b>15,164.71</b>
<b>(A)</b>	<b>15,666.93</b>	<b>15,164.71</b>
<b>Non-Current liabilities</b>		
- Provisions	38.50	38.80
<b>Current liabilities</b>		
<b>Financial Liabilities</b>		
- Borrowings	1,375.23	1,251.22
- Trade Payables		
Micro and Small Enterprises	-	-
Others	361.93	790.63
- Other Financial Liabilities	3.89	2.07
Provisions	111.72	87.41
Current Tax Liabilities [Net]	181.24	16.24
Other Current Liabilities	144.99	60.18
<b>(B)</b>	<b>2,217.50</b>	<b>2,246.55</b>
<b>TOTAL LIABILITIES (A + B)</b>	<b>17,884.43</b>	<b>17,411.26</b>

For and on behalf of the Board of Directors



*Mukund P. Mehta*

**Mukund P. Mehta**  
Managing Director



Place : Mumbai

Dated: 13th November, 2020

## KILITCH DRUGS (INDIA) LIMITED

### Cash Flow Statement for the half year ended 30th September 2020

Particulars	(Rs.in Lakhs)			
	half year ended 30th September 2020		Year Ended 31st March 2020	
	[Rs.]	[Rs.]	[Rs.]	[Rs.]
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net Profit / (Loss) before extraordinary items and tax		247.68		522.23
<i>Adjustments for:</i>				
Depreciation and amortisation	55.87		115.30	
Interest income	(121.61)		(195.69)	
Dividend income	(4.16)		(10.92)	
Interest paid	47.16		71.59	
(Profit)/Loss on sale of Investments	(35.65)		(181.94)	
Sundry Balances written back	(0.50)		(9.06)	
Provision for Gratuity & Leave Encashment	-		10.83	
Employee Stocks Option Cost	-		6.68	
Bad Debts / Provision for Doubtful Debts	137.66		(42.83)	
(Profit) / Loss from Investment in Partnership Firm	-		0.24	
Net unrealised exchange (gain) / loss	14.89	93.65	(132.30)	(368.09)
<b>Operating profit / (loss) before working capital changes</b>		<b>341.33</b>		<b>154.14</b>
<i>Changes in working capital:</i>				
<i>Operating Assets:</i>				
Inventories	334.40		(84.09)	
Trade receivables	(153.20)		789.11	
Other current assets	(226.13)		85.74	
Deposits & advances	2.82		(1.76)	
Other financial assets	1.67		8.50	
<i>Operating Liabilities:</i>				
Trade payables	(428.20)		252.79	
Other current liabilities	86.63		(182.27)	
Provisions	24.01	(358.00)	3.37	871.39
<b>Gross cash flow from / (used in) operating activities</b>		<b>(16.67)</b>		<b>1,025.53</b>
Direct Taxes (Paid) /refunded		(1.24)		(225.17)
<b>Net cash flow from / (used in) operating activities (A)</b>		<b>(17.91)</b>		<b>800.36</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				
Fixed assets purchased	(29.03)		(100.14)	
Loans/Advances to related Parties	(267.95)		(1,091.74)	
Proceeds (Net) from the sale of Current investments	40.66		(65.86)	
Proceeds (Net) from the sale of long-term investments	(18.13)		96.91	
Movement in other Bank balance	(103.52)		(53.83)	
Interest received	121.61		195.69	
Dividend received	4.16		10.92	
		(252.20)		(1,008.07)
		(252.20)		(1,008.07)
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>(252.20)</b>		<b>(1,008.07)</b>



<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from Shares issued [incl. ESOPs]	4.49		7.89	
Proceeds from Borrowings (Net of Repayments)	124.01		315.50	
Interest paid	(47.16)		(71.59)	
Dividends paid (Inclusive of tax on Dividend)	-		(179.03)	
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>81.34</b>		<b>72.77</b>
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>(188.77)</b>		<b>(134.94)</b>
Cash and cash equivalents at the beginning of the year		272.27		407.21
<b>Cash and cash equivalents at the end of the year</b>		<b>83.50</b>		<b>272.27</b>
<b>Cash and cash equivalents at the end of the year *</b>				
* Comprises:				
(a) Cash on hand		0.50		0.63
(b) Balances with banks				
(i) In current accounts		79.11		269.57
(ii) In earmarked accounts		3.89		2.07
		<b>83.50</b>		<b>272.27</b>

Place : Mumbai  
Dated: 13th November, 2020



For and on behalf of the Board of Directors

*Mukund P. Mehta*  
Mukund P. Mehta  
Managing Director



**A. M. GHELANI & COMPANY**  
**CHARTERED ACCOUNTANTS**

---

**Limited Review Report on Unaudited Quarterly/Half yearly Consolidated Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
**The Board of Directors of**  
**Kilitch Drugs (India) Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs (India) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended 30th September, 2020 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:

**List of Subsidiaries:**


1. Monarchy Healthserve Private Limited
2. Kilitch Estro Biotech PLC – Foreign Subsidiary





5. The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects total assets of Rs. 8,542.46 Lakhs as at 30<sup>th</sup> September, 2020, total revenues of Rs. 59.91 Lakhs and Rs. 59.91 Lakhs, total net profit after tax of Rs. 38.24 Lakhs and Rs. 38.24 Lakhs and total comprehensive income of Rs. 38.24 Lakhs and Rs. 38.24 Lakhs for the quarter ended 30th September, 2020 and for the period from 1<sup>st</sup> April, 2020 to 30th September, 2020, respectively, and Net Cash inflow of Rs. 24.58 Lakhs for the period from 1<sup>st</sup> April, 2020 to 30th September, 2020. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management. Our conclusion on the Statement is not modified in respect of the above matter.
6. We draw attention to Note 4 of the Statement, which describes the Group's management evaluation of impact of Covid 19 pandemic on the its business, logistics etc. The Management has made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter/half year ended 30th September, 2020.  
Our conclusion on the Statement is not modified in respect of these matters.
7. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A. M. Ghelani & Company**  
Chartered Accountants  
Firm Registration No. 103173W

  
**Chintan A. Ghelani**  
Partner

Membership No. 104391

ICAI UDIN: 20104391AAAAFG6386

Place : Mumbai

Date : 13<sup>th</sup> November, 2020




# KILITCH DRUGS (INDIA) LIMITED

## STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2020

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701  
Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

(Rs. In Lakhs)

Sr. No.	Particulars	CONSOLIDATED					
		Three Months Ended		Six Months Ended		Year Ended	
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
<b>1</b>	<b>Income</b>						
	Net Sales/Income from Operations	1,807.20	1,019.17	1,533.51	2,826.37	2,576.70	5,332.00
	Other Income	42.21	36.95	58.53	79.16	196.42	412.55
	<b>Total Income</b>	<b>1,849.41</b>	<b>1,056.12</b>	<b>1,592.14</b>	<b>2,905.53</b>	<b>2,773.12</b>	<b>5,744.55</b>
<b>2</b>	<b>Expenses</b>						
	Cost of Materials Consumed	771.22	671.10	698.79	1,442.32	1,447.76	2,982.03
	Variation in inventories of finished goods, work-in-progress and Stock-in-Trade	81.53	51.20	37.78	132.73	(67.29)	(73.48)
	Employee Benefit Expenses	132.23	115.46	139.86	247.69	273.30	569.01
	Finance Cost	17.84	29.32	16.44	47.16	31.54	71.59
	Depreciation and Amortisation Expenses	49.58	48.55	45.08	98.13	88.71	199.90
	Export Product Registration/Commission	76.58	50.20	85.99	126.78	210.87	448.15
	Other expenses	449.89	242.43	399.94	692.32	614.05	1,386.62
	<b>Total Expenses</b>	<b>1,578.87</b>	<b>1,208.26</b>	<b>1,423.88</b>	<b>2,787.13</b>	<b>2,598.94</b>	<b>5,583.82</b>
<b>3</b>	<b>Profit/(Loss) before Exceptional items (1-2)</b>	<b>270.54</b>	<b>(152.14)</b>	<b>168.26</b>	<b>118.40</b>	<b>174.18</b>	<b>160.73</b>
<b>4</b>	Exceptional Items	-	-	-	-	-	-
<b>5</b>	<b>Profit/(Loss) from ordinary activities before tax (3+4)</b>	<b>270.54</b>	<b>(152.14)</b>	<b>168.26</b>	<b>118.40</b>	<b>174.18</b>	<b>160.73</b>
<b>6</b>	Less : Tax Expenses	67.50	-	42.90	67.50	47.55	69.58
	Current Income Tax	(17.75)	(18.77)	(8.41)	(36.52)	12.21	6.95
	Deferred Tax						
<b>7</b>	<b>Profit/(Loss) after tax for the period from continuing operations (5-6)</b>	<b>220.79</b>	<b>(133.37)</b>	<b>133.77</b>	<b>87.42</b>	<b>114.42</b>	<b>84.20</b>
<b>8</b>	Other Comprehensive Income (after Tax)	96.59	184.43	(27.44)	281.02	(64.65)	(310.91)
<b>9</b>	<b>Total Comprehensive Income (after taxes) (7+8)</b>	<b>317.38</b>	<b>51.06</b>	<b>106.33</b>	<b>368.44</b>	<b>49.77</b>	<b>(226.71)</b>
<b>10</b>	<b>Net Profit / (Loss) attributable to</b>						
	a) Owner of the Company	208.17	(133.37)	133.77	74.80	114.42	84.20



11	b) Non Controlling interest	12.62	-	-	12.62	-	-
	<b>Other Comprehensive Income attributable to</b>						
	a) Owner of the Company	96.59	184.43	(27.44)	281.02	(64.65)	(310.91)
	b) Non Controlling interest	-	-	-	-	-	-
12	<b>Total Income attributable to</b>						
	a) Owner of the Company	304.76	51.06	106.33	355.82	49.77	(226.71)
	b) Non Controlling interest	12.62	-	-	12.62	-	-
13	<b>Paid-Up equity share capital (Face Value Rs. 10 per share)</b>	1,547.91	1,547.91	1,543.42	1,547.91	1,543.42	1,543.42
14	<b>Other Equity</b>						
15	<b>Earning per share</b>						
	(a) Basic (not annualised)	1.34	(0.86)	0.87	0.48	0.74	0.55
	(b) Diluted (not annualised)	1.34	(0.86)	0.87	0.48	0.74	0.55

**Notes:**

- The above Unaudited Consolidated Financial Results of the Company for the quarter and half year ended 30th September, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13th November, 2020.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The Group continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. The Management has exercised due care and made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter/half year ended 30th September, 2020. The Group based on current estimates expects to recover the carrying amount of the above assets, net of provisions established.

- In view of the uncertainties regarding the nature and duration of the ongoing COVID-19 Pandemic, we are unable to predict the future impact on our business operations. However, the Group will continue to closely monitor the situation and take appropriate measures in an attempt to mitigate any adverse impact on its operations. The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place: Mumbai  
Date: 13th November, 2020



For and on behalf of the Board of Directors

*Mukund P. Mehta*  
Mukund P. Mehta  
Director



**KILITCH DRUGS (INDIA) LIMITED**

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2020

CIN:L24239MH1992PLC066718

(Rs. In Lacs)


Particulars	As at 30st September, 2020	As at 31st March, 2020
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and Equipment	846.37	873.23
Capital work-in-progress	6,773.47	2,960.14
Other Intangible assets	2,237.65	2,279.89
<b>Financial assets</b>		
- Investments	2,422.92	2,404.81
- Loans/Advances	163.90	36.02
- Other Financials Assets	157.35	53.83
Deferred tax assets (Net)	133.14	96.62
(A)	<b>12,734.80</b>	<b>8,704.54</b>
<b>Current assets</b>		
Inventories	221.27	555.67
<b>Financial assets</b>		
- Investments	3,155.80	2,781.04
- Trade and other receivables	1,701.26	1,585.89
- Cash and cash equivalents	114.91	279.66
- Other Financials Assets	0.87	66.15
Other current assets	522.11	310.15
(B)	<b>5,716.22</b>	<b>5,578.56</b>
<b>TOTAL ASSETS (A + B)</b>	<b>18,451.02</b>	<b>14,283.10</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share capital	1,547.91	1,543.42
Other Equity	10,648.19	10,281.85
<b>Equity attributable to the owners</b>	<b>12,196.10</b>	<b>11,825.27</b>
Non-controlling interest	239.64	221.83
(A)	<b>12,435.74</b>	<b>12,047.10</b>
<b>Liabilities</b>		
<b>Non - Current Liabilities</b>		
Provisions	38.50	38.80
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
- Borrowings	1,384.93	1,260.92
- Trade Payables		
Micro and Small Enterprises	-	-
Others	4,090.83	710.38
- Other financial liabilities	60.48	3.50



Other current liabilities	145.26	118.40
(B)	6,015.28	2,236.01
<b>TOTAL EQUITY AND LIABILITIES ( A + B )</b>	<b>18,451.02</b>	<b>14,283.10</b>

Place : Mumbai  
Date : 13th November, 2020



For and on behalf of the Board of Directors  
  
**Mukund P. Mehta**  
Managing Director



**KILITCH DRUGS (INDIA) LIMITED**
**CONSOLIDATED CASH FLOW STATEMENT FOR THE SIX MONTHS ENDED ON 30TH SEPTEMBER, 2020**

Rs. (In Lacs)

Particulars	For the Six Months ended 30th September, 2020		For the Year ended 31st March, 2020	
	[Rs.]	[Rs.]	[Rs.]	[Rs.]
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net Profit / (Loss) before extraordinary items and tax		118.40		160.73
Adjustments for:				
Depreciation and amortisation	98.13		199.90	
Interest income	(7.01)		(16.42)	
Dividend income	(4.16)		(10.92)	
Interest paid	47.16		71.59	
(Profit)/Loss on sale of Investments	(35.65)		(181.94)	
Share of (Profit)/ Loss from Partnership Firm	-		0.24	
Sundry Balances written back	(0.50)		(9.06)	
ESOP cost	-		6.68	
Provision for Gratuity & Leave Encashment	0.00		10.86	
Bad Debts / Provision for Doubtful Debts	137.50		(42.68)	
Net unrealised exchange (gain) / loss	20.89		(150.90)	
<b>Operating profit / (loss) before working capital changes</b>		256.36		(122.63)
		374.76		38.10
<u>Changes in working capital:</u>				
<u>Operating Assets:</u>				
Inventories	334.40		(84.09)	
Trade receivables	(273.76)		551.28	
Other financial Assets	65.27		(10.14)	
Other current assets	(211.96)		70.88	
Deposits/Advances	(127.89)		(1.76)	
<u>Operating Liabilities:</u>				
Trade payables	3,380.96		284.82	
Other financial liabilities	54.90		1.43	
Other current liabilities	26.86		(182.57)	
Short-term provisions	25.96		3.34	
		3,274.74		633.17
Gross cash flow from / (used in) operating activities		3,649.50		671.27
Direct Taxes (Paid) / refunded		(1.23)		(225.17)
<b>Net cash flow from / (used in) operating activities</b>		<b>3,648.28</b>		<b>446.10</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>				




Capital expenditure on fixed assets, including capital advance	(3,842.35)		(1,049.93)	
Proceeds (Net) from the sale of Current investments	40.66		(65.87)	
(Purchase)/Sale (Net) of long-term investments:	(18.13)		96.91	
Movement in other Bank balance	(103.52)		(53.83)	
Interest received	7.01		16.42	
Dividend received	4.16		10.92	
<b>Net cash flow from / (used in) investing activities (B)</b>		<b>(3,912.17)</b>		<b>(1,045.40)</b>
		<b>(3,912.17)</b>		<b>(1,045.40)</b>
		<b>(3,912.17)</b>		<b>(1,045.40)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>				
Proceeds from Shares issued	4.49		7.90	
Proceeds from Borrowings	124.01		315.50	
Interest paid	(47.16)		(71.59)	
Proceeds from Minorities	17.81		12.17	
Dividends paid(Inclusive of tax on Dividend)	-	99.15	(179.03)	84.95
<b>Net cash flow from / (used in) financing activities (C)</b>		<b>99.15</b>		<b>84.95</b>
<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>		<b>(164.75)</b>		<b>(514.35)</b>
<b>Cash and cash equivalents at the beginning of the period</b>		<b>279.66</b>		<b>794.01</b>
<b>Cash and cash equivalents at the end of the period</b>		<b>114.91</b>		<b>279.66</b>
Cash and cash equivalents at the end of the period *				
* Comprises:				
(a) Cash on hand		0.75		0.89
(b) Balances with banks		110.27		276.70
(i) In current accounts		3.89		2.07
(ii) In earmarked accounts		<b>114.91</b>		<b>279.66</b>



For and on behalf of the Board of Directors

*Mukund P. Mehta*  
**Mukund P. Mehta**  
 (Managing Director)



Mumbai

Date: 13th November, 2020